- 全部删除
- 您的购物车当前为空
ML347 (LDN 193719) 是一种选择性的 ALK1/ALK2 抑制剂,它们的 IC50 分别为 46/32 nM,比对 ALK3 的抑制性高 300 倍。
为众多的药物研发团队赋能,
让新药发现更简单!
ML347 (LDN 193719) 是一种选择性的 ALK1/ALK2 抑制剂,它们的 IC50 分别为 46/32 nM,比对 ALK3 的抑制性高 300 倍。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 215 | In stock | |
2 mg | ¥ 297 | In stock | |
5 mg | ¥ 496 | In stock | |
10 mg | ¥ 745 | In stock | |
25 mg | ¥ 1,480 | In stock | |
50 mg | ¥ 2,880 | In stock | |
100 mg | ¥ 4,170 | In stock |
ML347 相关产品
产品描述 | ML347 (LDN 193719)(DN193719) is a highly specific ALK1/2 inhibitor ( IC50: 46/32 nM), and the selectivity for ALK2 is >300-fold than ALK3. |
靶点活性 | ALK1:46 nM, ALK2:32 nM, BMPR1A:10800 nM |
体内活性 | 在人类和大鼠血浆中,ML347与血浆蛋白的结合力较高。ML347在BMP应答的C2C12BRA细胞中也有一定效能(IC50:15 nM)。 |
激酶实验 | Kinase assay: All kinase assays are conducted by Reaction Biology Corp. In brief, compounds are tested at 10 concentrations by 3-fold serial dilutions starting at 30 μM, using nonspecific kinase inhibitor staurosporine as control. In vitro kinase reactions are carried out in the presence of 10 μM (33P)γATP. Five kinases tested are the human BMP type-I receptor activin receptor-like kinase 2 (ALK-2/ACVR1), the human TGFβ type-I receptor activin receptor-like kinase 5 (Alk5/TGFβR1), the human VEGF type-II receptor (KDR/Flk-1/VEGFR2), the human AMP-activated protein kinase (AMPK/A1/B1/G1) and the human platelet-derived growth factor receptor-β (PDGFRβ). |
别名 | LDN 193719 |
分子量 | 352.39 |
分子式 | C22H16N4O |
CAS No. | 1062368-49-3 |
Smiles | COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12 |
密度 | no data available |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||
溶解度信息 | DMSO: 1 mg/mL (2.84 mM), Sonication is recommended. ![]() | ||||||||||
溶液配制表 | |||||||||||
DMSO
|
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
评论内容